TY - JOUR
T1 - The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck
AU - Kupferman, Michael E.
AU - Kubik, Mark W.
AU - Bradford, Carol R.
AU - Civantos, Francisco J.
AU - Devaney, Kenneth O.
AU - Medina, Jesus E.
AU - Rinaldo, Alessandra
AU - Stoeckli, Sandro J.
AU - Takes, Robert P.
AU - Ferlito, Alfio
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2014
Y1 - 2014
N2 - From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.
AB - From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.
UR - http://www.scopus.com/inward/record.url?scp=84896700326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896700326&partnerID=8YFLogxK
U2 - 10.1016/j.amjoto.2013.12.004
DO - 10.1016/j.amjoto.2013.12.004
M3 - Review article
C2 - 24439782
AN - SCOPUS:84896700326
SN - 0196-0709
VL - 35
SP - 226
EP - 232
JO - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
JF - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
IS - 2
ER -